Members of management of Surgery Partners will be meeting with investors, January 9, 2023, as part of the 41st Annual J.P. Morgan Healthcare Conference, including a presentation at 8:15 p.m. ET. Based on results through November 2022, the Company is re-affirming its 2022 Adjusted EBITDA guidance of $375 million to $385 million and its 2022 Revenue guidance of $2.50 billion to $2.55 billion.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SGRY:
- Surgery Partners, Inc. Reaffirms 2022 Full Year Guidance
- Surgery Partners, Inc. To Present At Upcoming Investor Conference
- Surgery Partners price target lowered to $47 from $60 at Benchmark
- Surgery Partners, Inc. Announces Pricing of Upsized $575 Million Public Offering of Common Stock and $225 Million Concurrent Private Placement to Bain Capital
- Surgery Partners, Inc. Announces Proposed Public Offering of Common Stock
